ASCO: AstraZeneca’s Tagrisso, headed for big sales boost, cuts lung cancer recurrence by 83%

In mid-April, at the recommendation of an Independent Data Monitoring Committee, AstraZeneca unblinded a phase 3 trial of Tagrisso two years early. And now, the public is getting a look at what promp… [+3345 chars]Source